The potential of BTKi therapies in progressive forms of MS

🔬 BTK Inhibition in Progressive MS: What Does the Future Hold?

In this expert-led, on-demand activity, internationally recognized neurologist Prof. Xavier Montalban explores the emerging role of Bruton’s tyrosine kinaseinhibitors (BTKis) as a potential therapeutic approach to address key unmet needs in progressive multiple sclerosis (MS).

💡 Key insights include:
✅ Pathophysiological drivers of progressive MS
✅ Why non-active progressive MS remains a treatment challenge
✅ Scientific rationale for targeting BTK
✅ Emerging clinical trial data on investigational BTKis
✅ How BTKis could potentially fit within current treatment models

🎥 Watch the full activity on demand to stay informed of the evolving landscape of MS treatment.
👉 https://touchneurologyime.org/btkis-i...

This activity is funded by an independent medical education grant from Sanofi.

The activity is jointly provided by USF Health and touchIME
.
touchIME is an EBAC® accredited provider.

#MultipleSclerosis #ProgressiveMS #BTKi #NeuroScience #MSResearch #MSCare #MedicalEducation #Neurology